Insulet (PODD)
(Delayed Data from NSDQ)
$166.19 USD
+2.02 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$166.19 USD
+2.02 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Insulet Receives FDA Approval for ACE Pump Implementation
by Zacks Equity Research
FDA's approval will enable Insulet (PODD) to boost its insulin management business.
Why Is Insulet (PODD) Up 17.3% Since Last Earnings Report?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Insulet (PODD) has various favorable factors to maintain the current high.
Insulet (PODD) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
Insulet (PODD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's Why You Should Hold Onto Insulet (PODD) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Insulet's (PODD) solid prospects.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Insulet (PODD) Misses on Q2 Earnings, Ups '19 Revenue View
by Zacks Equity Research
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.
Insulet (PODD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -33.33% and 8.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Insulet (PODD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Insulet (PODD) Hits 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.
Insulet (PODD) Up 27.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.
Insulet (PODD) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 250.00% and 3.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why the Earnings Surprise Streak Could Continue for Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Insulet (PODD) Up 5.1% Since Last Earnings Report?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet Gains on Omnipod Reimbursement Update, Rivalry Stiff
by Zacks Equity Research
Insulet Corporation (PODD) continues to expand Omnipod's market access on growing reimbursements. The company operates in a highly competitive environment.
Insulet (PODD) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in Store for GW Pharma (GWPH) This Earnings Season?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 50.00% and 1.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?